Last reviewed · How we verify

NCT03790306

Opioid Free and Therapy Minimized Advantages Using HANA Table for Total Hip Arthroplasty

Completed Results posted Last updated 10 November 2020
What this trial tests

trial in Arthropathy of Hip Joint in 207 participants. Completed in 30 March 2020.

Timeline
15 January 2019
Primary endpoint
24 January 2020
30 March 2020

Quick facts

Lead sponsorSt. Elizabeth Medical Center, Utica, NY
StatusCompleted
Study typeOBSERVATIONAL
Enrollment207
Start date15 January 2019
Primary completion24 January 2020
Estimated completion30 March 2020
Sites1 location across United States

Conditions studied

Sponsor

St. Elizabeth Medical Center, Utica, NY

Who can join

Adults 30 to 100, any sex, with Arthropathy of Hip Joint or Osteoarthritis, Hip. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Pre-operative Narcotic Use Primary · Pre-operatively

Percentage of patients that used used opioids pre-operatively

GroupValue95% CI
THR With HANA Table30
Number of Patients That Took Any Opioids Throughout 6-week Follow-up Period Primary · 6 weeks

Number of patients that took any opioids throughout 6-week follow-up period

GroupValue95% CI
THR With HANA Table128
Short Physical Performance Battery Primary · 6 Weeks

Assessment tool measuring gait speed, balance and chair stand test. Scores range from 0 to 4 with higher scores indicating a better outcome.

Balance
GroupValue95% CI
THR With HANA Table3.95± 0.31
Gait
GroupValue95% CI
THR With HANA Table3.89± 0.45
Chair
GroupValue95% CI
THR With HANA Table3.17± 1.31
Numeric Pain Scores Secondary · 6 Weeks

A numeric pain score (0-10, 0 is no pain and 10 is worst imaginable pain). This will be used to assess patients level of pain relating to opioid use and recovery. Both 'best' pain level and 'worst' pain level as reported by the patient will be reported.

Best pain level
GroupValue95% CI
THR With HANA Table0.00966± 0.139
Worst pain level
GroupValue95% CI
THR With HANA Table2.14± 1.77
Sleep Quality Secondary · 6 Weeks

The percentage of patients where pain interrupts sleep 'never' or 'rarely' will be combined together and reported.

GroupValue95% CI
THR With HANA Table184
Number of Participants Who Adhere to Prescribed Post op Recovery Protocol Secondary · 2 weeks

Number of Participants Who Adhere to Prescribed Post op Recovery Protocol collected via a questionnaire

GroupValue95% CI
THR With HANA Table206
Length of Stay in Hospital Secondary · 1 week

Average number of days in hospital after surgery

GroupValue95% CI
THR With HANA Table0.41750 – 6
Number of Patients That Return to Work 6 Weeks After Surgery Secondary · 6 weeks

questionnaire asking the patient to report whether or not they have returned to employment and at what capacity (using Department of Labor physical employment scale). Patients will answer "yes" or "no" when asked if they have returned to work.

GroupValue95% CI
THR With HANA Table56
Number of Patients Who Return to Driving 6 Weeks After Surgery Secondary · 6 Weeks

Patients will respond yes or no when asked if they have resumed driving.

GroupValue95% CI
THR With HANA Table182

Sponsor's own description

To prove that anterior approach total hip arthroplasty using the HANA table can be performed with little, if any, need for opioids using a combination of education, optimized pre op and post op pain protocols and optimized recovery tools.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other St. Elizabeth Medical Center, Utica, NY trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03790306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing